Bayer, Curadev Enter ‘STING’ Pact Exploring Inflammatory Disease
Duo Using Curadev’s Stimulator Of Interferon Genes Antagonist Platform
Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.
